<DOC>
	<DOCNO>NCT02260635</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know evacetrapib Japanese participant primary hypercholesterolemia . The double blind treatment period last 12 week open-label extension period last additional 40 week .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Japanese Participants With Primary Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Japanese outpatient diagnose primary hypercholesterolemia LDLC level ( measure direct method baseline ) meet follow criterion . ( Participant category base definition Japan Atherosclerosis Society 2012 guideline . ) Category I : 160 mg/deciliter ( dL ) ≤LDLC &lt; 200 mg/dL Category II : 140 mg/dL≤LDLC &lt; 175 mg/dL Category III : 120 mg/dL≤LDLC &lt; 150 mg/dL Have triglyceride ( TG ) ≤400 mg/dL . Have HDLC &lt; 100 mg/dL . Participants LDL apheresis plasma apheresis . Participants secondary hypercholesterolemia familial hypercholesterolemia . Any planned angiography . If angiography plan , participant may screen enrol planned procedure complete . History follow condition : Stable angina acute coronary syndrome ( unstable angina , myocardial infarction ) , old myocardial infarction coronary revascularization procedure include stent placement , symptomatic carotid artery disease peripheral arterial disease ischemic stroke transient ischemic attack ( TIA ) intracranial hemorrhage abdominal aortic aneurysm Have systolic blood pressure ( SBP ) &gt; 160 millimeter mercury ( mm Hg ) diastolic blood pressure ( DBP ) &gt; 100 mm Hg . Have hemoglobin A1c ≥8.4 % ( National Glycohemoglobin Standardization Program ) . During study period , participant plan use , likely require , unwilling unable stop adequate washout prescription , counter medication , supplement health food intent treat serum lipid ( LDLC , HDLC , TG ) include limited class drug : statin , ezetimibe , bile acid sequestrant , eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) . Participants take probucol , fibrate nicotinic agent within 8 week screen exclude study . Have expose cholesteryl ester transfer protein inhibitor ( e.g. , anacetrapib dalcetrapib ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>